Immuron C. difficile study shows 100% survival
19 September, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has reported a 100% survival rate from animal trials of the C. difficile treatment candidate it is developing with Monash University.
Biota, Nabi amend merger terms to placate shareholder
18 September, 2012 by Dylan Bushell-EmblingBiota Holdings (ASX:BTA) and US-based Nabi Pharmaceuticals have amended the terms of their proposed merger, in a bid to placate Nabi shareholders seeking to block the deal.
Nexvet raises $2.5m to fund human-to-animal drugs
18 September, 2012 by Dylan Bushell-EmblingNexvet Biopharma has closed a $2.5 million seed financing round, after receiving an investment from the universities-led Trans Tasman Commercialisation Fund (TTCF).
New joint initiative to promote biotech and GM in agriculture
18 September, 2012 by Tim DeanA new industry group, the Agricultural Biotechnology Council of Australia (ABCA) has been formed to promote and encourage debate on the use of biotechnology and gene technology in agriculture in Australia.
Nominations called for Janssen 2012 Industry Excellence Awards
18 September, 2012 by AusBiotechJanssen & AusBiotech are pleased to announce that the Janssen 2012 Industry Excellence Awards, in three categories, are now open for nominations.
Bionomics acquires American cancer stem cell company
17 September, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has acquired US-based cancer stem cell drug development company Eclipse Therapeutics in a deal worth US$10 million ($9.5 million).
Priceline to stock Cellmid hair growth range
14 September, 2012 by Dylan Bushell-EmblingCellmid (ASX:CDY) subsidiary Advangen has now secured agreements with over 700 pharmacies including Priceline stores to stock its evolis line of hair growth products.
AusBiotech makes submission on R&D Tax Incentive quarterly payments
13 September, 2012 by AusBiotechAusBiotech has been advocating for quarterly payments since its first submission on the Tax Credit and is pleased to see the Government responsive to the cash-flow needs of small companies, giving companies the ability to smooth out cash-flow over the year and provide increased predictability.
Phylogica looks to recoup $1.9m from R&D Tax Incentive
13 September, 2012 by Dylan Bushell-EmblingThe first wave of companies is beginning to take advantage of the government’s recently installed R&D Tax Incentive, with Phylogica (ASX:PYC) lodging an application to recoup $1.9 million in research and development costs.
Bioniche FY12 loss doubles to $24m
13 September, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) said its net loss for FY12 nearly doubled to C$24.1 million ($23.6 million), even as revenue from its animal health division grew by over 10%.
Phylogica wins cosmetics deal for peptides
12 September, 2012 by Dylan Bushell-EmblingPhylogica (ASX:PYC) is continuing its push into the cosmetics market with a deal to license a phylomer peptide with skin repair potential to US-based luxury beauty product company Le Métier de Beauté.
CSL wins flu vaccine contract in US
12 September, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) subsidiary CSL Biotherapies has won a flu vaccine contract with the US health department that could be worth as much as US$1.5 billion in the event of a pandemic.
Highly-specialised BD course with subsidy for approved Victorian companies
11 September, 2012 by AusBiotechGlobal business development (BD) ‘guru,’ Jack Anthony, will visit the AusBiotech 2012 national conference to run a not-to-be-missed professional development course for BD professionals: ‘The Secret Sauce of Deal Making’.
Bacteriophage companies AmpliPhi and SPH to merge
11 September, 2012 by Dylan Bushell-EmblingUS-based AmpliPhi Biosciences and Australia's Special Phage Holdings (SPH) have revealed plans to merge to create a global bacteriophage-based therapy company.
Patrys closes $2.85m capital raising
10 September, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed the share purchase plan component of a capital raising worth $2.85 million. The clinical stage biopharmaceutical company fell just shy of hitting the maximum target for the capital raising of $2.9 million.
